Not known Facts About YX-2-107
The primary end place was the protection and tolerability of sifalimumab. Treatment-emergent adverse situations (AEs) and critical AEs (SAEs) as well as their severity, end result, and any relationship to your research medication were being recorded with the investigator throughout the review. AEs had been viewed as prone to be connected to researc